Daily brief

Teva beats and raises; the shekel slides; Trump ends the $4B US aid

Teva's Q3 revenue $4.4B vs $4.2B expected, 2026 outlook raised to $16.7-17B; the shekel at NIS 3.154, its weakest since late March.

Today in Israel - and what it all means for the business community at home and abroad.

TV10 Global Editorial · Tuesday, November 3, 2026

Quick takes

  • Teva: Q3 revenue $4.4B vs $4.2B expected, non-GAAP EPS $0.86 vs $0.72; 2026 revenue outlook raised to $16.7-17B (Globes).

  • Shekel: NIS 3.154 per dollar in afternoon trading, its weakest since late March; about 4.5% weaker since the 27 October election (Globes).

  • US aid: President Trump says he agreed with Prime Minister Netanyahu to stop the annual $4B in aid (TV10, citing Fox News).

  • Tower: expands its optical-chip partnership with Innolight for AI data centers (TV10).

  • Almeda Ventures: sells TailorMed for about $7.6M, 3.15 times its cost (TV10).

Earnings: Teva beats and raises again

Teva reported third-quarter revenue of $4.4 billion, above the $4.2 billion analysts expected, and non-GAAP earnings of $0.86 a share against a $0.72 consensus. Revenue was about 2% lower than a year earlier, and GAAP net profit fell 46% to $233 million, while non-GAAP net profit rose 11.3%. The company raised its 2026 revenue outlook for the second quarter in a row, to $16.7-17 billion from $16.5-16.85 billion. Its three growth brands grew 33% to about $1.1 billion: Austedo $751 million, Ajovy $269 million and Uzedy $85 million. Debt stands at $16.7 billion after a $4.9 billion bond refinancing.

Separately, Teva signed a deal with South Korea’s Samsung Bioepis for US commercial rights to two FDA-approved biosimilars: ETICOVO, a version of Enbrel, and infliximab-abda, a version of Remicade. The rights pass to Teva on closing and in the third quarter of 2027, and the parties expect to complete the deal by the end of 2026.

Original (Hebrew): https://tv10.co.il/news/israel/health/126674/ · Globes: https://en.globes.co.il/en/article-1001561824

Our take: The gap between GAAP and non-GAAP profit is still wide, so the number to watch is how fast the three branded drugs grow, not the headline profit.

Currency: the shekel hits a seven-month low

The dollar rose about 0.5% to NIS 3.154 in afternoon inter-bank trading, the shekel’s weakest level since late March. Globes says the shekel has lost about 4.5% since the 27 October election and 3.4% over the past month. Analysts cited political uncertainty over forming a government or holding new elections, concern about Iran, falling stocks on Wall Street, and wider interest-rate differentials, as US rate cuts are delayed. Exporters that earn in dollars and pay costs in shekels gain; importers and consumers pay more.

Original (Hebrew): https://tv10.co.il/news/coins/forex/126669/ · Globes: https://en.globes.co.il/en/article-1001561817

Our take: A weaker shekel is a margin boost for exporters and a cost for consumers. It is a story about uncertainty, not about a change in Israel’s fundamentals.

US aid: Trump says the $4B stops

In a Fox News interview on US midterm election day, President Trump said he had agreed with Prime Minister Netanyahu to stop the annual $4 billion in security aid, arguing that Israel is a rich country that no longer needs direct budget support. He said the US would still help if needed. TV10 notes that Mr. Netanyahu said something similar in an interview on Channel 10, telling Israelis to prepare for a change in American support. The aid has been a core part of the Israel Defense Forces’ procurement, much of it spent with American defense companies. We did not find a formal confirmation or timetable in the sources we checked.

Original (Hebrew): https://tv10.co.il/news/global/126679/

Our take: Treat this as a stated position, not a signed change. It matters for the defense budget and for how markets price Israeli risk, and the details are still to come.

Short updates

Watch list

  • Tue 3 Nov: US midterm elections.

  • Wed 4 Nov: Camtek reports; official Israeli election results are due.

  • Thu 5 Nov: Nova and El Al report.

For information only. Not investment advice. Sources are cited in each section; figures are as reported at the time of writing.